Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:BON NASDAQ:CASI NASDAQ:MTEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.74$0.83$0.55▼$2.22$9.18M1.5103,187 shs131,524 shsBONBon Natural Life$1.18$1.26$1.10▼$3.40$9.58M-0.1720,366 shs12,527 shsCASICASI Pharmaceuticals$0.21$0.21$0.21▼$3.09$2.55M0.91482,532 shsN/AMTEXMannatech$5.16$5.09$3.80▼$12.45$9.96M0.7215,245 shs3,742 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics0.00%-6.20%-5.36%+3.58%-56.41%BONBon Natural Life0.00%+4.34%-7.09%-7.89%-19.25%CASICASI Pharmaceuticals0.00%0.00%0.00%+0.00%-84.40%MTEXMannatech0.00%+1.78%-8.51%-10.88%-43.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.74$0.83$0.55▼$2.22$9.18M1.5103,187 shs131,524 shsBONBon Natural Life$1.18$1.26$1.10▼$3.40$9.58M-0.1720,366 shs12,527 shsCASICASI Pharmaceuticals$0.21$0.21$0.21▼$3.09$2.55M0.91482,532 shsN/AMTEXMannatech$5.16$5.09$3.80▼$12.45$9.96M0.7215,245 shs3,742 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics0.00%-6.20%-5.36%+3.58%-56.41%BONBon Natural Life0.00%+4.34%-7.09%-7.89%-19.25%CASICASI Pharmaceuticals0.00%0.00%0.00%+0.00%-84.40%MTEXMannatech0.00%+1.78%-8.51%-10.88%-43.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.40Hold$4.07448.81% UpsideBONBon Natural Life 1.00SellN/AN/ACASICASI Pharmaceuticals 2.00Hold$4.001,827.71% UpsideMTEXMannatech 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CASI, APRE, MTEX, and BON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/26/2026BONBon Natural Life Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/11/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.005/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.004/20/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K31.63N/AN/A$1.52 per share0.49BONBon Natural Life$18.67M0.51N/AN/A$7.13 per share0.17CASICASI Pharmaceuticals$26.85M0.10N/AN/A$0.12 per share1.73MTEXMannatech$108.04M0.09N/AN/A($2.75) per share-1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)BONBon Natural Life-$2MN/AN/AN/AN/AN/AN/AN/AN/ACASICASI Pharmaceuticals-$39.26M-$3.01N/AN/AN/A-183.93%N/A-131.54%N/AMTEXMannatech-$15.21M-$6.71N/AN/AN/A-11.97%-2,383.34%-40.24%N/ALatest CASI, APRE, MTEX, and BON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q4 2025MTEXMannatechN/A$0.49N/A$0.49N/A$24.92 million5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 millionN/A4/15/2026Q4 2025MTEXMannatechN/A-$5.94N/A-$5.94N/A$26.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ABONBon Natural LifeN/AN/AN/AN/AN/ACASICASI PharmaceuticalsN/AN/AN/AN/AN/AMTEXMannatech$0.203.88%-100.00%N/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A8.928.92BONBon Natural LifeN/AN/AN/ACASICASI PharmaceuticalsN/A0.300.24MTEXMannatechN/A1.090.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%BONBon Natural Life0.57%CASICASI Pharmaceuticals22.23%MTEXMannatech12.98%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics10.49%BONBon Natural Life26.48%CASICASI Pharmaceuticals21.24%MTEXMannatech41.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million11.08 millionNo DataBONBon Natural Life1008.13 million5.98 millionN/ACASICASI Pharmaceuticals18012.30 million9.69 millionOptionableMTEXMannatech2501.93 million1.13 millionNot OptionableCASI, APRE, MTEX, and BON HeadlinesRecent News About These CompaniesMannatech (NASDAQ:MTEX) Stock Price Passes Below 200-Day Moving Average - Should You Sell?June 30, 2026 | americanbankingnews.comMannatech Announces Appointment of Yasir Haider as Chief Financial OfficerJune 8, 2026 | globenewswire.comMannatech, Incorporated Announces Successful Approval of All Proposals at Annual Shareholder MeetingJune 3, 2026 | quiverquant.comQMannatech Announces Results of Annual Shareholders' MeetingJune 3, 2026 | globenewswire.comInsider Buying: Mannatech (NASDAQ:MTEX) Director Acquires 2,803 Shares of StockMay 22, 2026 | insidertrades.comInsider Buying: Mannatech (NASDAQ:MTEX) Director Acquires 5,000 Shares of StockMay 21, 2026 | insidertrades.comMannatech Stock Price HistoryMay 20, 2026 | investing.comMannatech Reports Financial Results for First Quarter 2026May 14, 2026 | globenewswire.comMannatech Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | markets.businessinsider.comMannatech, Incorporated Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | quiverquant.comQMannatech Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | globenewswire.comMannatech, IncorporatedApril 8, 2026 | edition.cnn.comMannatech Delays 10-K Filing Amid Going-Concern ReviewApril 2, 2026 | tipranks.comMannatech Announces Notification of Late FilingApril 1, 2026 | markets.businessinsider.comMannatech Inc. Reports Improved Quarterly Earnings Amid Sales DeclineNovember 13, 2025 | msn.comMannatech Reports Financial Results for Third Quarter 2025November 12, 2025 | globenewswire.comMicro-Cap Mannatech Stock Draws Frenzied Retail Buzz As Traders Pounce On 'Tiny Float' PlayOctober 13, 2025 | msn.comMannatech Extends Loan Repayment to March 2027September 12, 2025 | tipranks.comMannatech trading halted, volatility trading pauseAugust 14, 2025 | msn.comMannatech Reports Financial Results for Second Quarter 2025August 12, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCASI, APRE, MTEX, and BON Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.74 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.78 +0.04 (+5.26%) As of 07/2/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Bon Natural Life NASDAQ:BON$1.18 0.00 (0.00%) Closing price 07/2/2026 03:51 PM EasternExtended Trading$1.19 +0.01 (+0.85%) As of 07/2/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.CASI Pharmaceuticals NASDAQ:CASI$0.21 0.00 (0.00%) As of 07/2/2026CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Mannatech NASDAQ:MTEX$5.16 0.00 (0.00%) As of 07/2/2026 04:00 PM EasternMannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
